Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection
Related Experiment Video
Updated: Dec 7, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Amanda L Blackmon1, Lauren Pinter-Brown1,2
1Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Irvine, CA, USA.
Abstract:
Advanced cutaneous T cell lymphomas (CTCL) including mycosis fungoides (MF) and Sézary syndrome (SS) are often difficult to manage once they become resistant to initial systemic treatment. Current systemic treatments usually provide a limited duration of disease control, leaving this an area in desperate need of new treatment options for better long-term control. These conditions often affect the older population where transplantation may not be a feasible option. Recent studies evaluated a novel CCR4 humanized monoclonal antibody, mogamulizumab, in relapsed/refractory MF and SS, which show a meaningful progression free survival (PFS) benefit. In August 2018, mogamulizumab was approved by the FDA for the treatment of patients with relapsed/refractory MF/SS who have failed at least one treatment. Approval was based on the Phase III MAVORIC study comparing mogamulizumab to vorinostat, an FDA approved drug for this indication, in 372 patients. In this trial, mogamulizumab was found to have a superior PFS with a median of 7.7 months compared to 3.1 months in the vorinostat arm, with a hazard ratio of 0.53, p<0.001. Mogamulizumab was well tolerated with the most common AE being infusion-related reactions (32%), drug rash (20%), diarrhea (23%), and fatigue (22%). We reviewed the literature leading to the development and approval of mogamulizumab and suggest which patients may benefit the most from this treatment.
Insights
Mogamulizumab offers improved progression-free survival for advanced cutaneous T-cell lymphomas (CTCL) resistant to other treatments. This novel antibody provides a new option for patients with mycosis fungoides (MF) and Sézary syndrome (SS).
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Advanced cutaneous T-cell lymphomas (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS), present significant management challenges, especially upon treatment resistance.
- Existing systemic therapies offer limited disease control, highlighting an unmet need for durable treatment options, particularly in older populations unsuitable for transplantation.
Purpose of the Study:
- To review the development and FDA approval of mogamulizumab, a CCR4 humanized monoclonal antibody, for relapsed/refractory MF and SS.
- To evaluate the efficacy and safety of mogamulizumab compared to vorinostat in patients with advanced CTCL.
Main Methods:
- The MAVORIC study, a Phase III trial, randomized 372 patients with relapsed/refractory MF/SS to receive either mogamulizumab or vorinostat.
- Progression-free survival (PFS) was the primary endpoint, with secondary endpoints including overall response rate and safety.
Main Results:
- Mogamulizumab demonstrated a statistically significant improvement in PFS, with a median of 7.7 months compared to 3.1 months for vorinostat (hazard ratio: 0.53, p<0.001).
- Mogamulizumab was generally well-tolerated, with common adverse events including infusion-related reactions, rash, diarrhea, and fatigue.
Conclusions:
- Mogamulizumab is an effective and well-tolerated treatment option for patients with relapsed/refractory MF/SS who have failed prior systemic therapy.
- This novel antibody represents a significant advancement in the long-term management of advanced CTCL, offering improved disease control.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF